Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies.
Saved in:
| Title: | Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies. |
|---|---|
| Authors: | Zang Y; School of Medical Laboratory, Shandong Second Medical University., Weifang, China., Cheng HE; School of Medical Laboratory, Shandong Second Medical University., Weifang, China., Sun Y; Department of Hematology, Weifang People's Hospital, Weifang, China., Wang J; School of Medical Laboratory, Shandong Second Medical University., Weifang, China., Zhao Y; School of Medical Laboratory, Shandong Second Medical University., Weifang, China., Yang J; School of Medical Laboratory, Shandong Second Medical University., Weifang, China., Liu Y; Neurologic Disorders and Regenerative Repair Laboratory, Shandong Second Medical University, Weifang, China.; School of Basic Medical Sciences, Shandong Second Medical University, Weifang, China., Sun Y; School of Medical Laboratory, Shandong Second Medical University., Weifang, China. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jan 06; Vol. 15, pp. 1591759. Date of Electronic Publication: 2026 Jan 06 (Print Publication: 2025). |
| Publication Type: | Journal Article; Systematic Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1591759 |
